The drumbeat of renal failure: Symbiosis of prevention and renal replacement therapy

Blood Purification

Volumn 22, Issue 1, 2004, Pages 6-8

  Dirks, John H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiovascular disease; Chronic kidney disease, prevention; Diabetes; Kidney disease, progression; Renin angiotensin blockade

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; GLOMERULONEPHRITIS; HEALTH STATUS; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY TRANSPLANTATION; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REMISSION; SMOKING HABIT;

DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY;

EID: 0942268709     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074917     Document Type: Article

References (25)

1. Moeller S, Gioberge S, Brown G: ESRD patients in 2001: Global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002;17:2071-2076.
2. Sakhuja V, Sud K: End-stage renal disease in India and Pakistan: Burden of disease and management issues. Kidney Int 2003;63(suppl 83):S115-S118.
3. De Vecchi A, Dratwa M, Wiedmann ME: Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: Costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999;14:31-41.
4. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;44:795-808.
5. Berthoux F, Jones E, Gellert R, Mendel S, Saker L, Briggs D: Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: Report of the European Renal Association Registry and the National Registries. Nephrol Dial Transplant 1999;14:2332-2342.
6. Rutkowski R: Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant 2000;15:156-160.
7. Yusuf S, Reddy S, Ounpuu S, Anand S: Global burden of cardiovascular diseases. 1. General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-2753.
8. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-1608.
9. Brenner BM: Remission of renal disease: Recounting the challenge, acquiring the goal. J Clin Invest 2002;110:1753-1758.
10. World Health Organization: Wellcome Trust Meeting Report on Secondary Prevention. Secondary Prevention of Major Noncommunicable Diseases through Community-Based and Health Services Interventions. Cambridge, WHO, 2001.
11. World Health Organization: WHO CVD-Risk Management Package for Low- and Medium-Resource Settings. Geneva, WHO, 2002.
12. Orth SR, Stockmann A, Conradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schafer K, Sieberth HG, Wanner C, Watschinger B, Zucchelli P: Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998;54:926-931.
13. Douglas JG, Agodoa L: ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int 2003;63(suppl 83):S74-S76.
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
15. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GIS-EN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-1863.
16. Usami T, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, Kimura G: Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney Int 2003;64:1445-1449.
17. World Health Organization: Integrated Management of Cardiovascular Risk: Report of a WHO Meeting. Geneva, WHO, 9-12 July, 2002.
18. Mani MK: Clinical and epidemiological programme on renal disease. Nephrol Dial Transplant 1999;14:1807-1808.
19. Schieppati A, Perico N, Remuzzi G: Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. Nephrol Dial Transplant 2003;18:858-859.
20. Mani MK: Prevention of chronic renal failure at the community level. Kidney Int 2003;63(suppl 83):S86-S89.
21. Brown W, Collins A, Chen S, King K, Molony D, Gannon MR, Politoski G, Keane WF: Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program. Kidney Int 2003;63(suppl 83):S50-S55.
22. Ramirez SPB, Hsu SIH, McClellan W: Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program. Kidney Int 2003;63(suppl 83):S61-S65.
23. Hoy W, Wang Z, Baker PRA, Kelly AM: Reduction in national death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int 2003;63(suppl 83):S66-S73.
24. Plata R, Silva C, Jahuita J, Perez L, Schieppati A, Remuzzi G: The first clinical and epidemiological programme on renal disease in Bolivia: A model for prevention and early diagnosis of renal diseases in developing countries. Nephrol Dial Transplant 1998;13:3034-3036.
25. Hoy W, Baker PR, Kelly AM, Wang Z: Reducing premature death and renal failure in Australian aboriginals. A community-based cardiovascular and renal protective program. Med J Aust 2000;172:473-478.